title: Chronic Therapy With Elamipretide (MTP-131), a Novel Mitochondria-Targeting Peptide, Improves Left Ventricular and Mitochondrial Function in Dogs With Advanced Heart Failure.
abstract: BACKGROUND
  Elamipretide (MTP-131), a novel mitochondria-targeting peptide, was shown to reduce infarct size in animals with myocardial infarction and improve renal function in pigs with acute and chronic kidney injury. This study examined the effects of chronic therapy with elamipretide on left ventricular (LV) and mitochondrial function in dogs with heart failure (HF).
  
  
  RESULTS
  Fourteen dogs with microembolization-induced HF were randomized to 3 months monotherapy with subcutaneous injections of elamipretide (0.5 mg/kg once daily, HF+ELA, n=7) or saline (control, HF-CON, n=7). LV ejection fraction, plasma n-terminal pro-brain natriuretic peptide, tumor necrosis factor-α, and C-reactive protein were measured before (pretreatment) and 3 months after initiating therapy (post-treatment). Mitochondrial respiration, membrane potential (Δψm), maximum rate of ATP synthesis, and ATP/ADP ratio were measured in isolated LV cardiomyocytes obtained at post-treatment. In HF-CON dogs, ejection fraction decreased at post-treatment compared with pretreatment (29 ± 1% versus 31 ± 2%), whereas in HF+ELA dogs, ejection fraction significantly increased at post-treatment compared with pretreatment (36 ± 2% versus 30 ± 2%; P<0.05). In HF-CON, n-terminal pro-brain natriuretic peptide increased by 88 ± 120 pg/mL during follow-up but decreased significantly by 774 ± 85 pg/mL in HF+ELA dogs (P<0.001). Treatment with elamipretide also normalized plasma tumor necrosis factor-α and C-reactive protein and restored mitochondrial state-3 respiration, Δψm, rate of ATP synthesis, and ATP/ADP ratio (ATP/ADP: 0.38 ± 0.04 HF-CON versus 1.16 ± 0.15 HF+ELA; P<0.001).
  
  
  CONCLUSIONS
  Long-term therapy with elamipretide improves LV systolic function, normalizes plasma biomarkers, and reverses mitochondrial abnormalities in LV myocardium of dogs with advanced HF. The results support the development of elamipretide for the treatment of HF.
authors.affiliation: From the Department of Medicine, Division of Cardiovascular Medicine, Henry Ford Hospital, Detroit, MI. hsabbah1@hfhs.org.
authors.forename: Hani N
authors.initials: HN
authors.lastname: Sabbah
authors.affiliation: From the Department of Medicine, Division of Cardiovascular Medicine, Henry Ford Hospital, Detroit, MI.
authors.forename: Ramesh C
authors.initials: RC
authors.lastname: Gupta
authors.affiliation: From the Department of Medicine, Division of Cardiovascular Medicine, Henry Ford Hospital, Detroit, MI.
authors.forename: Smita
authors.initials: S
authors.lastname: Kohli
authors.affiliation: From the Department of Medicine, Division of Cardiovascular Medicine, Henry Ford Hospital, Detroit, MI.
authors.forename: Mengjun
authors.initials: M
authors.lastname: Wang
authors.affiliation: From the Department of Medicine, Division of Cardiovascular Medicine, Henry Ford Hospital, Detroit, MI.
authors.forename: Souheila
authors.initials: S
authors.lastname: Hachem
authors.affiliation: From the Department of Medicine, Division of Cardiovascular Medicine, Henry Ford Hospital, Detroit, MI.
authors.forename: Kefei
authors.initials: K
authors.lastname: Zhang
mesh_terms: D000818:Animals; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism; D004195:Disease Models, Animal; D004285:Dogs; D004734:Energy Metabolism / Q000187:drug effects; D006333:Heart Failure / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D007262:Infusions, Intravenous; D007279:Injections, Subcutaneous; D053078:Membrane Potential, Mitochondrial / Q000187:drug effects; D008929:Mitochondria, Heart / Q000187:drug effects* / Q000378:metabolism; D032383:Myocytes, Cardiac / Q000187:drug effects* / Q000378:metabolism; D020097:Natriuretic Peptide, Brain / Q000097:blood; D009842:Oligopeptides / Q000008:administration & dosage / Q000494:pharmacology*; D010446:Peptide Fragments / Q000097:blood; D017382:Reactive Oxygen Species / Q000378:metabolism; D020127:Recovery of Function; D013318:Stroke Volume / Q000187:drug effects; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000097:blood; D018487:Ventricular Dysfunction, Left / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D016277:Ventricular Function, Left / Q000187:drug effects*
chemical_list: D015415:Biomarkers; D009842:Oligopeptides; D010446:Peptide Fragments; D017382:Reactive Oxygen Species; D014409:Tumor Necrosis Factor-alpha; C506540:arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide; C109794:pro-brain natriuretic peptide (1-76); D020097:Natriuretic Peptide, Brain; D002097:C-Reactive Protein
keywords: cardiolipin; heart failure; mitochondria; myocardial energetics; ventricular function
references.citation: Hypertension. 2012 Nov;60(5):1242-9
references.pmid: 23045468
references.citation: J Am Soc Nephrol. 2013 Jul;24(8):1250-61
references.pmid: 23813215
references.citation: Circulation. 1996 Jun 1;93(11):1946-50
references.pmid: 8640966
references.citation: J Clin Invest. 1997 Apr 15;99(8):1926-35
references.pmid: 9109437
references.citation: Am J Physiol. 1991 Apr;260(4 Pt 2):H1379-84
references.pmid: 1826414
references.citation: Biochim Biophys Acta. 2015 Jun-Jul;1847(6-7):587-98
references.pmid: 25843549
references.citation: J Biol Chem. 2012 May 18;287(21):17589-97
references.pmid: 22433850
references.citation: Am J Pathol. 1996 Jan;148(1):141-9
references.pmid: 8546201
references.citation: Antioxid Redox Signal. 2009 Sep;11(9):2095-104
references.pmid: 19203217
references.citation: J Appl Physiol (1985). 2013 Aug 15;115(4):529-38
references.pmid: 23766499
references.citation: Circ Res. 2012 Apr 13;110(8):1109-24
references.pmid: 22499901
references.citation: Circulation. 1994 Jun;89(6):2852-9
references.pmid: 8205701
references.citation: Pharmacol Ther. 2013 Dec;140(3):258-66
references.pmid: 23867906
references.citation: Aging Cell. 2013 Oct;12(5):763-71
references.pmid: 23692570
references.citation: J Pharmacol Exp Ther. 2003 Jan;304(1):425-32
references.pmid: 12490619
references.citation: J Cell Biol. 2009 Sep 21;186(6):793-803
references.pmid: 19752025
references.citation: Circ Res. 2012 Sep 28;111(8):1091-106
references.pmid: 23023511
references.citation: J Mol Cell Cardiol. 2007 Jan;42(1):150-8
references.pmid: 17070837
references.citation: J Mol Cell Cardiol. 1998 Sep;30(9):1757-62
references.pmid: 9769231
references.citation: J Am Heart Assoc. 2012 Jun;1(3):e001644
references.pmid: 23130143
references.citation: Cardiovasc Res. 2008 Oct 1;80(1):30-9
references.pmid: 18710878
references.citation: J Mol Cell Cardiol. 2000 Dec;32(12):2361-7
references.pmid: 11113011
references.citation: J Androl. 2001 Jul-Aug;22(4):568-74
references.pmid: 11451353
references.citation: J Cardiovasc Pharmacol Ther. 2014 Jan;19(1):121-32
references.pmid: 24288396
references.citation: Biochem J. 2010 Apr 1;427(1):105-12
references.pmid: 20100174
references.citation: Cardiology. 2009;112(4):294-302
references.pmid: 18832825
references.citation: Biochim Biophys Acta. 2009 Nov;1787(11):1402-15
references.pmid: 19168026
references.citation: Am J Physiol. 1999 Apr;276(4 Pt 2):H1385-92
references.pmid: 10199866
references.citation: J Biol Chem. 2004 Aug 13;279(33):34682-90
references.pmid: 15178689
references.citation: J Am Soc Nephrol. 2011 Jun;22(6):1041-52
references.pmid: 21546574
references.citation: J Physiol. 2005 Dec 1;569(Pt 2):467-73
references.pmid: 16254011
references.citation: Circ Heart Fail. 2013 Sep 1;6(5):1067-76
references.pmid: 23935006
references.citation: Mol Cell Biochem. 1995 Jun 7-21;147(1-2):29-34
references.pmid: 7494551
references.citation: J Mol Cell Cardiol. 1992 Nov;24(11):1333-47
references.pmid: 1479624
references.citation: Chem Phys Lipids. 2014 Apr;179:75-81
references.pmid: 24189589
references.citation: Circulation. 2000 Oct 17;102(16):1990-5
references.pmid: 11034950